Translational Development Acquisition Corp. (NASDAQ: TDAC) Stock Competitors & Peer Comparison
See TDAC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Shell Companies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TDAC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TDAC | $10.85 | -0.09% | 267.2M | 42.78 | $0.25 | N/A |
| CCIV | $24.25 | +5.90% | 44.4B | N/A | N/A | N/A |
| PSACU | $17.08 | +0.35% | 12B | -108.79 | -$0.16 | N/A |
| RTPY | $9.91 | -0.30% | 11.6B | N/A | N/A | N/A |
| LVRAW | $0.04 | +0.00% | 11.5B | N/A | N/A | N/A |
| CMLFU | $13.00 | -4.55% | 10.3B | -1444.44 | -$0.01 | N/A |
| PSAC | $13.78 | -0.36% | 9.7B | N/A | N/A | N/A |
| GRSVU | $11.39 | +3.36% | 6.8B | N/A | N/A | N/A |
| APSG | $7.39 | -25.88% | 6.3B | 36.95 | $0.20 | N/A |
| RTP | $10.03 | -4.48% | 6.3B | N/A | N/A | N/A |
Stock Comparison
Lucid Group, Inc. (NYSE: CCIV)
TDAC vs CCIV Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CCIV has a market cap of 44.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CCIV trades at $24.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CCIV's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to CCIV's ROE of -13.92%. Regarding short-term risk, TDAC is less volatile compared to CCIV. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CCIV's competition here
Property Solutions Acquisition Corp. (NASDAQ: PSACU)
TDAC vs PSACU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, PSACU has a market cap of 12B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while PSACU trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas PSACU's P/E ratio is -108.79. In terms of profitability, TDAC's ROE is +0.03%, compared to PSACU's ROE of +118.85%. Regarding short-term risk, TDAC is less volatile compared to PSACU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check PSACU's competition here
Reinvent Technology Partners Y (NASDAQ: RTPY)
TDAC vs RTPY Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, RTPY has a market cap of 11.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while RTPY trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas RTPY's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to RTPY's ROE of -0.43%. Regarding short-term risk, TDAC is less volatile compared to RTPY. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check RTPY's competition here
Levere Holdings Corp. (NASDAQ: LVRAW)
TDAC vs LVRAW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, LVRAW has a market cap of 11.5B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while LVRAW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas LVRAW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to LVRAW's ROE of N/A. Regarding short-term risk, TDAC is less volatile compared to LVRAW. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check LVRAW's competition here
CM Life Sciences, Inc. (NASDAQ: CMLFU)
TDAC vs CMLFU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CMLFU has a market cap of 10.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CMLFU trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CMLFU's P/E ratio is -1444.44. In terms of profitability, TDAC's ROE is +0.03%, compared to CMLFU's ROE of -0.39%. Regarding short-term risk, TDAC is less volatile compared to CMLFU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CMLFU's competition here
Property Solutions Acquisition Corp. (NASDAQ: PSAC)
TDAC vs PSAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, PSAC has a market cap of 9.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while PSAC trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas PSAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to PSAC's ROE of +118.85%. Regarding short-term risk, TDAC is less volatile compared to PSAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check PSAC's competition here
Gores Holdings V, Inc. (NASDAQ: GRSVU)
TDAC vs GRSVU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GRSVU has a market cap of 6.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GRSVU trades at $11.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GRSVU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to GRSVU's ROE of +0.00%. Regarding short-term risk, TDAC is more volatile compared to GRSVU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check GRSVU's competition here
Apollo Strategic Growth Capital (NYSE: APSG)
TDAC vs APSG Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, APSG has a market cap of 6.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while APSG trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas APSG's P/E ratio is 36.95. In terms of profitability, TDAC's ROE is +0.03%, compared to APSG's ROE of +0.03%. Regarding short-term risk, TDAC is less volatile compared to APSG. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check APSG's competition here
Reinvent Technology Partners (NYSE: RTP)
TDAC vs RTP Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, RTP has a market cap of 6.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while RTP trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas RTP's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to RTP's ROE of -0.58%. Regarding short-term risk, TDAC is less volatile compared to RTP. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check RTP's competition here
Dragoneer Growth Opportunities Corp. (NYSE: DGNR)
TDAC vs DGNR Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DGNR has a market cap of 5.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DGNR trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DGNR's P/E ratio is -308.67. In terms of profitability, TDAC's ROE is +0.03%, compared to DGNR's ROE of +0.02%. Regarding short-term risk, TDAC is less volatile compared to DGNR. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DGNR's competition here
VectoIQ Acquisition Corp. II (NASDAQ: VTIQ)
TDAC vs VTIQ Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, VTIQ has a market cap of 5.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while VTIQ trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas VTIQ's P/E ratio is 91.50. In terms of profitability, TDAC's ROE is +0.03%, compared to VTIQ's ROE of +472.81%. Regarding short-term risk, TDAC is more volatile compared to VTIQ. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check VTIQ's competition here
VectoIQ Acquisition Corp. II (NASDAQ: VTIQU)
TDAC vs VTIQU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, VTIQU has a market cap of 5.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while VTIQU trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas VTIQU's P/E ratio is 100.60. In terms of profitability, TDAC's ROE is +0.03%, compared to VTIQU's ROE of +472.81%. Regarding short-term risk, TDAC is more volatile compared to VTIQU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check VTIQU's competition here
Vector Acquisition Corporation (NASDAQ: VACQ)
TDAC vs VACQ Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, VACQ has a market cap of 5.5B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while VACQ trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas VACQ's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to VACQ's ROE of -0.08%. Regarding short-term risk, TDAC is less volatile compared to VACQ. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check VACQ's competition here
SVF Investment Corp. 3 (NASDAQ: SVFC)
TDAC vs SVFC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SVFC has a market cap of 5.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SVFC trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SVFC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SVFC's ROE of +0.05%. Regarding short-term risk, TDAC is less volatile compared to SVFC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SVFC's competition here
VG Acquisition Corp. (NYSE: VGAC)
TDAC vs VGAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, VGAC has a market cap of 5B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while VGAC trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas VGAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to VGAC's ROE of -1.21%. Regarding short-term risk, TDAC is less volatile compared to VGAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check VGAC's competition here
CM Life Sciences III Inc. (NASDAQ: CMLT)
TDAC vs CMLT Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CMLT has a market cap of 4.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CMLT trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CMLT's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to CMLT's ROE of N/A. Regarding short-term risk, TDAC is less volatile compared to CMLT. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CMLT's competition here
Gores Holdings VI, Inc. (NASDAQ: GHVI)
TDAC vs GHVI Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GHVI has a market cap of 4.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GHVI trades at $14.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GHVI's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to GHVI's ROE of -1.28%. Regarding short-term risk, TDAC is less volatile compared to GHVI. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GHVI's competition here
Nextdoor Holdings, Inc. (NASDAQ: KVSB)
TDAC vs KVSB Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, KVSB has a market cap of 4.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while KVSB trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas KVSB's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to KVSB's ROE of -0.07%. Regarding short-term risk, TDAC is less volatile compared to KVSB. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check KVSB's competition here
FTAC Olympus Acquisition Corp. (NASDAQ: FTOCU)
TDAC vs FTOCU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FTOCU has a market cap of 4.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FTOCU trades at $11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FTOCU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FTOCU's ROE of +0.07%. Regarding short-term risk, TDAC is less volatile compared to FTOCU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FTOCU's competition here
Tuscan Holdings Corp. (NASDAQ: THCBU)
TDAC vs THCBU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, THCBU has a market cap of 3.9B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while THCBU trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas THCBU's P/E ratio is -101.87. In terms of profitability, TDAC's ROE is +0.03%, compared to THCBU's ROE of +0.01%. Regarding short-term risk, TDAC is less volatile compared to THCBU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check THCBU's competition here
Climate Change Crisis Real Impact I Acquisition Corporation (NYSE: CLII)
TDAC vs CLII Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CLII has a market cap of 3.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CLII trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CLII's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to CLII's ROE of -0.31%. Regarding short-term risk, TDAC is less volatile compared to CLII. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CLII's competition here
GreenVision Acquisition Corp. (NASDAQ: GRNV)
TDAC vs GRNV Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GRNV has a market cap of 3.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GRNV trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GRNV's P/E ratio is -59.68. In terms of profitability, TDAC's ROE is +0.03%, compared to GRNV's ROE of +0.05%. Regarding short-term risk, TDAC is less volatile compared to GRNV. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GRNV's competition here
Forest Road Acquisition Corp. (NYSE: FRX)
TDAC vs FRX Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FRX has a market cap of 3.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FRX trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FRX's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FRX's ROE of +0.39%. Regarding short-term risk, TDAC is less volatile compared to FRX. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FRX's competition here
Holicity Inc. (NASDAQ: HOLUU)
TDAC vs HOLUU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HOLUU has a market cap of 3.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HOLUU trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HOLUU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to HOLUU's ROE of -0.13%. Regarding short-term risk, TDAC is less volatile compared to HOLUU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check HOLUU's competition here
Silver Spike Acquisition Corp. (NASDAQ: SSPK)
TDAC vs SSPK Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SSPK has a market cap of 3.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SSPK trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SSPK's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SSPK's ROE of +0.04%. Regarding short-term risk, TDAC is less volatile compared to SSPK. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SSPK's competition here
Falcon Capital Acquisition Corp. (NASDAQ: FCACU)
TDAC vs FCACU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FCACU has a market cap of 3.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FCACU trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FCACU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FCACU's ROE of -0.00%. Regarding short-term risk, TDAC is less volatile compared to FCACU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FCACU's competition here
CF Acquisition Corp. VI (NASDAQ: CFVI)
TDAC vs CFVI Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CFVI has a market cap of 3.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CFVI trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CFVI's P/E ratio is -18.55. In terms of profitability, TDAC's ROE is +0.03%, compared to CFVI's ROE of -0.47%. Regarding short-term risk, TDAC is less volatile compared to CFVI. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CFVI's competition here
Holicity Inc. (NASDAQ: HOL)
TDAC vs HOL Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HOL has a market cap of 3.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HOL trades at $12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HOL's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to HOL's ROE of -0.13%. Regarding short-term risk, TDAC is less volatile compared to HOL. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check HOL's competition here
Tuscan Holdings Corp. (NASDAQ: THCB)
TDAC vs THCB Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, THCB has a market cap of 3.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while THCB trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas THCB's P/E ratio is -81.30. In terms of profitability, TDAC's ROE is +0.03%, compared to THCB's ROE of +0.01%. Regarding short-term risk, TDAC is less volatile compared to THCB. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check THCB's competition here
Sustainable Opportunities Acquisition Corp. (NYSE: SOAC)
TDAC vs SOAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SOAC has a market cap of 2.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SOAC trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SOAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SOAC's ROE of +0.53%. Regarding short-term risk, TDAC is less volatile compared to SOAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SOAC's competition here
Decarbonization Plus Acquisition Corporation (NASDAQ: DCRBU)
TDAC vs DCRBU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DCRBU has a market cap of 2.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DCRBU trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DCRBU's P/E ratio is -16.00. In terms of profitability, TDAC's ROE is +0.03%, compared to DCRBU's ROE of -0.84%. Regarding short-term risk, TDAC is less volatile compared to DCRBU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DCRBU's competition here
Ivanhoe Capital Acquisition Corp. (NYSE: IVAN)
TDAC vs IVAN Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, IVAN has a market cap of 2.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while IVAN trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas IVAN's P/E ratio is -698.18. In terms of profitability, TDAC's ROE is +0.03%, compared to IVAN's ROE of -0.33%. Regarding short-term risk, TDAC is less volatile compared to IVAN. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check IVAN's competition here
Good Works Acquisition Corp. (NASDAQ: GWAC)
TDAC vs GWAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GWAC has a market cap of 2.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GWAC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GWAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to GWAC's ROE of -0.59%. Regarding short-term risk, TDAC is less volatile compared to GWAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GWAC's competition here
Landcadia Holdings III, Inc (NASDAQ: LCYAU)
TDAC vs LCYAU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, LCYAU has a market cap of 2.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while LCYAU trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas LCYAU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to LCYAU's ROE of +0.04%. Regarding short-term risk, TDAC is more volatile compared to LCYAU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check LCYAU's competition here
Churchill Capital Corp XI Warrants (NASDAQ: CCXIW)
TDAC vs CCXIW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CCXIW has a market cap of 2.5B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CCXIW trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CCXIW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to CCXIW's ROE of N/A. Regarding short-term risk, TDAC is less volatile compared to CCXIW. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CCXIW's competition here
Fifth Wall Acquisition Corp. I (NASDAQ: FWAA)
TDAC vs FWAA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FWAA has a market cap of 2.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FWAA trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FWAA's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FWAA's ROE of -0.09%. Regarding short-term risk, TDAC is less volatile compared to FWAA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FWAA's competition here
GS Acquisition Holdings Corp II (NYSE: GSAH)
TDAC vs GSAH Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GSAH has a market cap of 2.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GSAH trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GSAH's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to GSAH's ROE of +0.42%. Regarding short-term risk, TDAC is less volatile compared to GSAH. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GSAH's competition here
Landcadia Holdings III, Inc (NASDAQ: LCY)
TDAC vs LCY Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, LCY has a market cap of 2.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while LCY trades at $12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas LCY's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to LCY's ROE of +0.04%. Regarding short-term risk, TDAC is less volatile compared to LCY. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check LCY's competition here
Foresight Acquisition Corp. (NASDAQ: FORE)
TDAC vs FORE Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FORE has a market cap of 2.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FORE trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FORE's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FORE's ROE of +3.90%. Regarding short-term risk, TDAC is less volatile compared to FORE. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FORE's competition here
Revolution Acceleration Acquisition Corp (NASDAQ: RAAC)
TDAC vs RAAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, RAAC has a market cap of 2.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while RAAC trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas RAAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to RAAC's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to RAAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check RAAC's competition here
Supernova Partners Acquisition Company, Inc. (NYSE: SPNV)
TDAC vs SPNV Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SPNV has a market cap of 2.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SPNV trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SPNV's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SPNV's ROE of -0.99%. Regarding short-term risk, TDAC is less volatile compared to SPNV. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SPNV's competition here
Social Capital Suvretta Holdings Corp. III (NASDAQ: DNAC)
TDAC vs DNAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DNAC has a market cap of 2.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DNAC trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DNAC's P/E ratio is -37.72. In terms of profitability, TDAC's ROE is +0.03%, compared to DNAC's ROE of -0.36%. Regarding short-term risk, TDAC is less volatile compared to DNAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DNAC's competition here
Fortress Value Acquisition Corp. II (NYSE: FAII)
TDAC vs FAII Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FAII has a market cap of 2.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FAII trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FAII's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FAII's ROE of -0.32%. Regarding short-term risk, TDAC is less volatile compared to FAII. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FAII's competition here
dMY Technology Group, Inc. III (NYSE: DMYI)
TDAC vs DMYI Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DMYI has a market cap of 2.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DMYI trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DMYI's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to DMYI's ROE of -0.16%. Regarding short-term risk, TDAC is less volatile compared to DMYI. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DMYI's competition here
Live Oak Acquisition Corp. II (NYSE: LOKB)
TDAC vs LOKB Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, LOKB has a market cap of 2.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while LOKB trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas LOKB's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to LOKB's ROE of -0.62%. Regarding short-term risk, TDAC is less volatile compared to LOKB. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check LOKB's competition here
Star Peak Corp II (NYSE: STPC)
TDAC vs STPC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, STPC has a market cap of 2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while STPC trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas STPC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to STPC's ROE of -0.29%. Regarding short-term risk, TDAC is less volatile compared to STPC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check STPC's competition here
Mudrick Capital Acquisition Corporation II (NASDAQ: MUDS)
TDAC vs MUDS Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, MUDS has a market cap of 2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while MUDS trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas MUDS's P/E ratio is 3.39. In terms of profitability, TDAC's ROE is +0.03%, compared to MUDS's ROE of -0.01%. Regarding short-term risk, TDAC is more volatile compared to MUDS. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check MUDS's competition here
Mudrick Capital Acquisition Corporation II (NASDAQ: MUDSU)
TDAC vs MUDSU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, MUDSU has a market cap of 2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while MUDSU trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas MUDSU's P/E ratio is -1125.56. In terms of profitability, TDAC's ROE is +0.03%, compared to MUDSU's ROE of -0.01%. Regarding short-term risk, TDAC is more volatile compared to MUDSU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check MUDSU's competition here
Tiga Acquisition Corp. (NYSE: TINV)
TDAC vs TINV Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, TINV has a market cap of 2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while TINV trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas TINV's P/E ratio is 30.61. In terms of profitability, TDAC's ROE is +0.03%, compared to TINV's ROE of +3.57%. Regarding short-term risk, TDAC is less volatile compared to TINV. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check TINV's competition here
Apex Treasury Corporation Class A (NASDAQ: APXT)
TDAC vs APXT Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, APXT has a market cap of 1.9B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while APXT trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas APXT's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to APXT's ROE of +0.16%. Regarding short-term risk, TDAC is more volatile compared to APXT. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check APXT's competition here
Apex Treasury Corporation (NASDAQ: APXTU)
TDAC vs APXTU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, APXTU has a market cap of 1.9B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while APXTU trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas APXTU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to APXTU's ROE of +0.16%. Regarding short-term risk, TDAC is more volatile compared to APXTU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check APXTU's competition here
Digital World Acquisition Corp. (NASDAQ: DWAC)
TDAC vs DWAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DWAC has a market cap of 1.9B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DWAC trades at $49.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DWAC's P/E ratio is -73.46. In terms of profitability, TDAC's ROE is +0.03%, compared to DWAC's ROE of -0.84%. Regarding short-term risk, TDAC is less volatile compared to DWAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DWAC's competition here
Digital World Acquisition Corp. (NASDAQ: DWACU)
TDAC vs DWACU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DWACU has a market cap of 1.9B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DWACU trades at $61.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DWACU's P/E ratio is -451.10. In terms of profitability, TDAC's ROE is +0.03%, compared to DWACU's ROE of -0.84%. Regarding short-term risk, TDAC is less volatile compared to DWACU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DWACU's competition here
Athena Technology Acquisition Corp. (NYSE: ATHN)
TDAC vs ATHN Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, ATHN has a market cap of 1.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while ATHN trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas ATHN's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to ATHN's ROE of +2.24%. Regarding short-term risk, TDAC is less volatile compared to ATHN. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check ATHN's competition here
Gores Metropoulos II, Inc. (NASDAQ: GMII)
TDAC vs GMII Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GMII has a market cap of 1.8B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GMII trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GMII's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to GMII's ROE of +0.21%. Regarding short-term risk, TDAC is less volatile compared to GMII. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GMII's competition here
Motive Capital Corp. (NYSE: MOTV)
TDAC vs MOTV Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, MOTV has a market cap of 1.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while MOTV trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas MOTV's P/E ratio is 55.86. In terms of profitability, TDAC's ROE is +0.03%, compared to MOTV's ROE of -0.23%. Regarding short-term risk, TDAC is less volatile compared to MOTV. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check MOTV's competition here
CBRE Acquisition Holdings, Inc. (NYSE: CBAH)
TDAC vs CBAH Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CBAH has a market cap of 1.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CBAH trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CBAH's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to CBAH's ROE of +0.04%. Regarding short-term risk, TDAC is less volatile compared to CBAH. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CBAH's competition here
GX Acquisition Corp. (NASDAQ: GXGXU)
TDAC vs GXGXU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GXGXU has a market cap of 1.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GXGXU trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GXGXU's P/E ratio is -23.73. In terms of profitability, TDAC's ROE is +0.03%, compared to GXGXU's ROE of -0.03%. Regarding short-term risk, TDAC is less volatile compared to GXGXU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GXGXU's competition here
One (NYSE: AONE)
TDAC vs AONE Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, AONE has a market cap of 1.7B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while AONE trades at $8.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas AONE's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to AONE's ROE of -17.11%. Regarding short-term risk, TDAC is less volatile compared to AONE. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check AONE's competition here
Tortoise Acquisition Corp. II (NYSE: SNPR)
TDAC vs SNPR Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SNPR has a market cap of 1.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SNPR trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SNPR's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SNPR's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to SNPR. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SNPR's competition here
Jaws Spitfire Acquisition Corporation (NYSE: SPFR)
TDAC vs SPFR Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SPFR has a market cap of 1.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SPFR trades at $8.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SPFR's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SPFR's ROE of -4.57%. Regarding short-term risk, TDAC is less volatile compared to SPFR. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SPFR's competition here
Apex Treasury Corporation (NASDAQ: APXTW)
TDAC vs APXTW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, APXTW has a market cap of 1.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while APXTW trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas APXTW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to APXTW's ROE of +0.16%. Regarding short-term risk, TDAC is more volatile compared to APXTW. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check APXTW's competition here
D8 Holdings Corp. (NYSE: DEH)
TDAC vs DEH Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DEH has a market cap of 1.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DEH trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DEH's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to DEH's ROE of -3.33%. Regarding short-term risk, TDAC is less volatile compared to DEH. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DEH's competition here
Rotor Acquisition Corp. (NYSE: ROT)
TDAC vs ROT Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, ROT has a market cap of 1.6B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while ROT trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas ROT's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to ROT's ROE of -0.45%. Regarding short-term risk, TDAC is less volatile compared to ROT. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check ROT's competition here
NextGen Acquisition Corporation (NASDAQ: NGAC)
TDAC vs NGAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, NGAC has a market cap of 1.5B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while NGAC trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas NGAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to NGAC's ROE of -0.80%. Regarding short-term risk, TDAC is less volatile compared to NGAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check NGAC's competition here
Celularity Inc. (NASDAQ: GXGX)
TDAC vs GXGX Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, GXGX has a market cap of 1.5B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while GXGX trades at $10.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas GXGX's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to GXGX's ROE of +4.12%. Regarding short-term risk, TDAC is less volatile compared to GXGX. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check GXGX's competition here
Hudson Executive Investment Corp. (NASDAQ: HECCU)
TDAC vs HECCU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HECCU has a market cap of 1.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HECCU trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HECCU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to HECCU's ROE of -0.10%. Regarding short-term risk, TDAC is less volatile compared to HECCU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check HECCU's competition here
Altimar Acquisition Corp. II (NYSE: ATMR)
TDAC vs ATMR Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, ATMR has a market cap of 1.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while ATMR trades at $10.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas ATMR's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to ATMR's ROE of +0.44%. Regarding short-term risk, TDAC is less volatile compared to ATMR. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check ATMR's competition here
Osprey Technology Acquisition Corp. (NYSE: SFTW)
TDAC vs SFTW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SFTW has a market cap of 1.4B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SFTW trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SFTW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SFTW's ROE of -0.56%. Regarding short-term risk, TDAC is less volatile compared to SFTW. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SFTW's competition here
890 5th Avenue Partners, Inc. (NASDAQ: ENFA)
TDAC vs ENFA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, ENFA has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while ENFA trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas ENFA's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to ENFA's ROE of -1.15%. Regarding short-term risk, TDAC is less volatile compared to ENFA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check ENFA's competition here
Environmental Impact Acquisition Corp. (NASDAQ: ENVI)
TDAC vs ENVI Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, ENVI has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while ENVI trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas ENVI's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to ENVI's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to ENVI. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check ENVI's competition here
ArcLight Clean Transition Corp. II (NASDAQ: ACTD)
TDAC vs ACTD Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, ACTD has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while ACTD trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas ACTD's P/E ratio is -25.50. In terms of profitability, TDAC's ROE is +0.03%, compared to ACTD's ROE of -0.00%. Regarding short-term risk, TDAC is less volatile compared to ACTD. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check ACTD's competition here
Vickers Vantage Corp. I (NASDAQ: VCKA)
TDAC vs VCKA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, VCKA has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while VCKA trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas VCKA's P/E ratio is 100.11. In terms of profitability, TDAC's ROE is +0.03%, compared to VCKA's ROE of +1.87%. Regarding short-term risk, TDAC is less volatile compared to VCKA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check VCKA's competition here
Thimble Point Acquisition Corp. (NASDAQ: THMA)
TDAC vs THMA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, THMA has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while THMA trades at $9.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas THMA's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to THMA's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to THMA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check THMA's competition here
L&F Acquisition Corp. (NYSE: LNFA)
TDAC vs LNFA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, LNFA has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while LNFA trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas LNFA's P/E ratio is 21.06. In terms of profitability, TDAC's ROE is +0.03%, compared to LNFA's ROE of +0.09%. Regarding short-term risk, TDAC is less volatile compared to LNFA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check LNFA's competition here
Fintech Acquisition Corp. IV (NASDAQ: FTIVU)
TDAC vs FTIVU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FTIVU has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FTIVU trades at $14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FTIVU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FTIVU's ROE of -0.14%. Regarding short-term risk, TDAC is less volatile compared to FTIVU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FTIVU's competition here
ACON S2 Acquisition Corp. (NASDAQ: STWO)
TDAC vs STWO Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, STWO has a market cap of 1.3B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while STWO trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas STWO's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to STWO's ROE of +4.68%. Regarding short-term risk, TDAC is less volatile compared to STWO. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check STWO's competition here
Haymaker Acquisition Corp. III (NASDAQ: HYACU)
TDAC vs HYACU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HYACU has a market cap of 1.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HYACU trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HYACU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to HYACU's ROE of -0.11%. Regarding short-term risk, TDAC is more volatile compared to HYACU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check HYACU's competition here
Fintech Acquisition Corp. IV (NASDAQ: FTIV)
TDAC vs FTIV Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FTIV has a market cap of 1.2B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FTIV trades at $13.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FTIV's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FTIV's ROE of -0.14%. Regarding short-term risk, TDAC is less volatile compared to FTIV. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FTIV's competition here
Alpha Healthcare Acquisition Corp. (NASDAQ: AHAC)
TDAC vs AHAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, AHAC has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while AHAC trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas AHAC's P/E ratio is -72.11. In terms of profitability, TDAC's ROE is +0.03%, compared to AHAC's ROE of -5.42%. Regarding short-term risk, TDAC is less volatile compared to AHAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check AHAC's competition here
Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC)
TDAC vs AMHC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, AMHC has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while AMHC trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas AMHC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to AMHC's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to AMHC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check AMHC's competition here
FTAC Hera Acquisition Corp. (NASDAQ: HERAW)
TDAC vs HERAW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HERAW has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HERAW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HERAW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to HERAW's ROE of +0.01%. Regarding short-term risk, TDAC is less volatile compared to HERAW. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check HERAW's competition here
FTAC Hera Acquisition Corp. (NASDAQ: HERA)
TDAC vs HERA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HERA has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HERA trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HERA's P/E ratio is 46.32. In terms of profitability, TDAC's ROE is +0.03%, compared to HERA's ROE of +0.01%. Regarding short-term risk, TDAC is more volatile compared to HERA. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check HERA's competition here
FG New America Acquisition Corp. (NYSE: FGNA)
TDAC vs FGNA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FGNA has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FGNA trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FGNA's P/E ratio is -4.35. In terms of profitability, TDAC's ROE is +0.03%, compared to FGNA's ROE of +0.46%. Regarding short-term risk, TDAC is less volatile compared to FGNA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check FGNA's competition here
Social Capital Suvretta Holdings Corp. I (NASDAQ: DNAA)
TDAC vs DNAA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, DNAA has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while DNAA trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas DNAA's P/E ratio is -54.53. In terms of profitability, TDAC's ROE is +0.03%, compared to DNAA's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to DNAA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check DNAA's competition here
Therapeutics Acquisition Corp. (NASDAQ: RACA)
TDAC vs RACA Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, RACA has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while RACA trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas RACA's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to RACA's ROE of +0.00%. Regarding short-term risk, TDAC is less volatile compared to RACA. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check RACA's competition here
Trebia Acquisition Corp. (NYSE: TREB)
TDAC vs TREB Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, TREB has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while TREB trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas TREB's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to TREB's ROE of -12.26%. Regarding short-term risk, TDAC is less volatile compared to TREB. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check TREB's competition here
TPG Pace Tech Opportunities Corp. (NYSE: PACE)
TDAC vs PACE Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, PACE has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while PACE trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas PACE's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to PACE's ROE of -1.52%. Regarding short-term risk, TDAC is less volatile compared to PACE. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check PACE's competition here
FTAC Hera Acquisition Corp. (NASDAQ: HERAU)
TDAC vs HERAU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, HERAU has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while HERAU trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas HERAU's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to HERAU's ROE of +0.01%. Regarding short-term risk, TDAC is more volatile compared to HERAU. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check HERAU's competition here
LifeSci Acquisition II Corp. (NASDAQ: LSAQ)
TDAC vs LSAQ Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, LSAQ has a market cap of 1.1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while LSAQ trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas LSAQ's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to LSAQ's ROE of N/A. Regarding short-term risk, TDAC is less volatile compared to LSAQ. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check LSAQ's competition here
Stable Road Acquisition Corp. (NASDAQ: SRAC)
TDAC vs SRAC Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SRAC has a market cap of 1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SRAC trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SRAC's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SRAC's ROE of -0.90%. Regarding short-term risk, TDAC is less volatile compared to SRAC. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SRAC's competition here
FTAC Parnassus Acquisition Corp. (NASDAQ: FTPAW)
TDAC vs FTPAW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, FTPAW has a market cap of 1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while FTPAW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas FTPAW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to FTPAW's ROE of -0.00%. Regarding short-term risk, TDAC is more volatile compared to FTPAW. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check FTPAW's competition here
Sandbridge Acquisition Corporation (NYSE: SBG)
TDAC vs SBG Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, SBG has a market cap of 1B. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while SBG trades at $8.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas SBG's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to SBG's ROE of -0.51%. Regarding short-term risk, TDAC is less volatile compared to SBG. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check SBG's competition here
Churchill Capital Corp VII (NYSE: CVII-WT)
TDAC vs CVII-WT Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CVII-WT has a market cap of 977.9M. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CVII-WT trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CVII-WT's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to CVII-WT's ROE of +0.02%. Regarding short-term risk, TDAC is more volatile compared to CVII-WT. This indicates higher risk in terms of short-term price fluctuations for TDAC.Check CVII-WT's competition here
Churchill Capital Corp VII (NYSE: CVII-UN)
TDAC vs CVII-UN Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CVII-UN has a market cap of 958.8M. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CVII-UN trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CVII-UN's P/E ratio is 64.65. In terms of profitability, TDAC's ROE is +0.03%, compared to CVII-UN's ROE of +0.02%. Regarding short-term risk, TDAC is less volatile compared to CVII-UN. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CVII-UN's competition here
Bleichroeder Acquisition Corp. II (NASDAQ: BBCQW)
TDAC vs BBCQW Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, BBCQW has a market cap of 954.5M. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while BBCQW trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas BBCQW's P/E ratio is N/A. In terms of profitability, TDAC's ROE is +0.03%, compared to BBCQW's ROE of N/A. Regarding short-term risk, TDAC is less volatile compared to BBCQW. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check BBCQW's competition here
B. Riley Principal 150 Merger Corp. (NASDAQ: BRPM)
TDAC vs BRPM Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, BRPM has a market cap of 944M. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while BRPM trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas BRPM's P/E ratio is -72.74. In terms of profitability, TDAC's ROE is +0.03%, compared to BRPM's ROE of +4.56%. Regarding short-term risk, TDAC is less volatile compared to BRPM. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check BRPM's competition here
Crescent Acquisition Corp. (NASDAQ: CRSAU)
TDAC vs CRSAU Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CRSAU has a market cap of 937.8M. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CRSAU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CRSAU's P/E ratio is -27.21. In terms of profitability, TDAC's ROE is +0.03%, compared to CRSAU's ROE of -0.34%. Regarding short-term risk, TDAC is less volatile compared to CRSAU. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CRSAU's competition here
Churchill Capital Corp VII (NYSE: CVII)
TDAC vs CVII Comparison September 2026
Translational Development Acquisition Corp. (NASDAQ: TDAC) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TDAC stands at 267.2M. In comparison, CVII has a market cap of 914.7M. Regarding current trading prices, TDAC is priced at $10.85 on the NASDAQ, while CVII trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TDAC currently has a P/E ratio of 42.78, whereas CVII's P/E ratio is 999.00. In terms of profitability, TDAC's ROE is +0.03%, compared to CVII's ROE of +0.02%. Regarding short-term risk, TDAC is less volatile compared to CVII. This indicates lower risk in terms of short-term price fluctuations for TDAC.Check CVII's competition here